Department of Advanced Medical Sciences & Technologies, School of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran.
Research Center for Noncommunicable Diseases, School of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran.
Mol Neurobiol. 2019 Dec;56(12):8489-8512. doi: 10.1007/s12035-019-01653-2. Epub 2019 Jul 1.
Neurodegenerative diseases (NDDs) include more than 600 types of nervous system disorders in humans that impact tens of millions of people worldwide. Estimates by the World Health Organization (WHO) suggest NDDs will increase by nearly 50% by 2030. Hence, development of advanced models for research on NDDs is needed to explore new therapeutic strategies and explore the pathogenesis of these disorders. Different approaches have been deployed in order to investigate nervous system disorders, including two-and three-dimensional (2D and 3D) cell cultures and animal models. However, these models have limitations, such as lacking cellular tension, fluid shear stress, and compression analysis; thus, studying the biochemical effects of therapeutic molecules on the biophysiological interactions of cells, tissues, and organs is problematic. The microfluidic "organ-on-a-chip" is an inexpensive and rapid analytical technology to create an effective tool for manipulation, monitoring, and assessment of cells, and investigating drug discovery, which enables the culture of various cells in a small amount of fluid (10 to 10 L). Thus, these chips have the ability to overcome the mentioned restrictions of 2D and 3D cell cultures, as well as animal models. Stem cells (SCs), particularly neural stem cells (NSCs), induced pluripotent stem cells (iPSCs), and embryonic stem cells (ESCs) have the capability to give rise to various neural system cells. Hence, microfluidic organ-on-a-chip and SCs can be used as potential research tools to study the treatment of central nervous system (CNS) and peripheral nervous system (PNS) disorders. Accordingly, in the present review, we discuss the latest progress in microfluidic brain-on-a-chip as a powerful and advanced technology that can be used in basic studies to investigate normal and abnormal functions of the nervous system.
神经退行性疾病(NDDs)包括人类超过 600 种神经系统疾病,影响着全球数千万人。世界卫生组织(WHO)的估计表明,到 2030 年,NDDs 将增加近 50%。因此,需要开发先进的 NDD 研究模型,以探索新的治疗策略并研究这些疾病的发病机制。为了研究神经系统疾病,已经采用了不同的方法,包括二维(2D)和三维(3D)细胞培养和动物模型。然而,这些模型存在一些局限性,例如缺乏细胞张力、流体剪切力和压缩分析;因此,研究治疗分子对细胞、组织和器官的生物物理相互作用的生化影响存在问题。微流控“器官芯片”是一种廉价且快速的分析技术,可以创建用于操纵、监测和评估细胞以及研究药物发现的有效工具,它可以在少量液体(10 到 100 微升)中培养各种细胞。因此,这些芯片具有克服 2D 和 3D 细胞培养以及动物模型所提到的限制的能力。干细胞(SCs),特别是神经干细胞(NSCs)、诱导多能干细胞(iPSCs)和胚胎干细胞(ESCs),具有分化为各种神经系统细胞的能力。因此,微流控器官芯片和 SCs 可以用作研究中枢神经系统(CNS)和周围神经系统(PNS)疾病治疗的潜在研究工具。因此,在本综述中,我们讨论了微流控脑芯片作为一种强大而先进的技术的最新进展,该技术可用于基础研究以研究神经系统的正常和异常功能。